The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Open accessAbstract
BACKGROUND: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. PATIENTS AND METHODS: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of ≤1 were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years, or six cycles of platinum plus pemetrexed chemotherapy. This report includes updated efficacy and safety outcomes, exploratory biomarker analyses including four-gene inflammatory expression signature score, and a post hoc efficacy analysis in patients who discontinued treatment due to treatment-related adverse events (TRAEs). RESULTS: With a median follow-up of 43.1 months, nivolumab plus ipilimumab continued to prolong OS versus chemotherapy. Median OS was 18.1 versus 14.1 months [hazard ratio (95% confidence interval), 0.73 (0.61-0.87)], and 3-year OS rates were 23% versus 15%, respectively. Three-year progression-free survival rates were 14% versus 1%, and objective response rates were 40% versus 44%. At 3 years, 28% versus 0% of responders had an ongoing response. Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. No new safety signals were observed with nivolumab plus ipilimumab, despite patients being off therapy for 1 year. In patients who discontinued nivolumab plus ipilimumab due to TRAEs, median OS was 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation. CONCLUSIONS: With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Self-citationFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Self-citationHellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095
Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Self-citationHellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30413-9 · Cited by 775
Borghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01605 · Cited by 656
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Self-citationDissecting the mechanisms of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0275-8 · Cited by 434
Maio, M., Scherpereel, A., Calabrò, L., Aerts, J., Perez, S. C., Bearz, A., Nackaerts, K., Fennell, D. A., Kowalski, D., Tsao, A. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30446-1 · Cited by 424
Self-citationTumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler, J. H., Hanks, B. A., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407
Paz-Ares, L. G., Ramalingam, S. S., Ciuleanu, T.-E., Lee, J.-S., Urban, L., Caro, R. B., Park, K., Sakai, H., Ohe, Y., Nishio, M., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.010 · Cited by 315
Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., Nye, M., Johnson, L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00471-x · Cited by 256
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Quispel-Janssen, J., van der Noort, V., de Vries, J. F., Zimmerman, M., Lalezari, F., Thunnissen, E., Monkhorst, K., Schouten, R., Schunselaar, L., Disselhorst, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.038 · Cited by 255
Self-citationDisselhorst, M. J., Quispel-Janssen, J., Lalezari, F., Monkhorst, K., de Vries, J. F., van der Noort, V., Harms, E., Burgers, S., & Baas, P. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30420-x · Cited by 250
Self-citationMansfield, A. S., Roden, A. C., Peikert, T., Sheinin, Y. M., Harrington, S. M., Krco, C. J., Dong, H., & Kwon, E. D. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000177 · Cited by 238
Self-citationKazandjian, D., Gong, Y., Keegan, P., Pazdur, R., & Blumenthal, G. M. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1747 · Cited by 235
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000891 · Cited by 224
Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100273 · Cited by 186
Self-citationNowak, A. K., Lesterhuis, W. J., Kok, P.-S., Brown, C., Hughes, B. G., Karikios, D. J., John, T., Kao, S. C.-H., Leslie, C., Cook, A. M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30462-9 · Cited by 167
Self-citationShao, C., Li, G., Huang, L., Pruitt, S. K., Castellanos, E. H., Frampton, G. M., Carson, K. R., Snow, T., Singal, G., Fabrizio, D. A., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25109 · Cited by 162
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 153
Forde, P. M., Anagnostou, V., Sun, Z., Dahlberg, S. E., Kindler, H. L., Niknafs, N., Purcell, T., Santana-Dávila, R., Dudek, A. Z., Borghaei, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01541-0 · Cited by 147
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Mansfield, A. S., Peikert, T., Smadbeck, J. B., Udell, J. B. M., Garcia-Rivera, E., Elsbernd, L. R., Erskine, C. L., Keulen, V. P. V., Kosari, F., Murphy, S. J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.001 · Cited by 138
Self-citationLei, M., Siemers, N. O., Pandya, D., Chang, H., Sánchez, T., Harbison, C. T., Szabó, P. M., Janjigian, Y. Y., Ott, P. A., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2790 · Cited by 97
Immunotherapy in Malignant Pleural Mesothelioma
de Gooijer, C. J., Borm, F. J., Scherpereel, A., & Baas, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00187 · Cited by 85
Self-citationRouquette, I., Clermont, E., Gilhodes, J., Bluthgen, M. V., Perallon, R., Chalabreysse, L., Muret, A. D., Hofman, V., Marx, A., Parrens, M., et al. (2019) · Biomarker Research · doi:10.1186/s40364-019-0177-8 · Cited by 52
Miyamoto, Y., Kozuki, T., Aoe, K., Wada, S., Harada, D., Yoshida, M., Sakùrai, J., Hotta, K., & Fujimoto, N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003288 · Cited by 29
Self-citationLei, M., Siemers, N. O., Pandya, D., Chang, H., Sánchez, T., Dorange, C., Harbison, C. T., Szabó, P. M., Janjigian, Y. Y., Ott, P. A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-2673 · Cited by 21
Cao, M., Zhang, J., Xu, H., Lin, Z., Chang, H., Wang, Y., Huang, X., Chen, X., Wang, H., & Song, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.608368 · Cited by 20
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
Lettieri, S., Bortolotto, C., Agustoni, F., Lococo, F., Lancia, A., Comoli, P., Corsico, A. G., & Stella, G. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051034 · Cited by 17
Ma, Y., Li, Q., Du, Y., Cai, J., Chen, W., Zhao, G., Liu, X., Li, H., Ma, L., Huang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640761 · Cited by 15
Research works printed but not linked: 1
- Forde, 2021, DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma - a phase 3 randomized trial, J Clin Oncol, 39, 10.1200/JCO.2021.39.15_suppl.TPS8586 · doi:10.1200/jco.2021.39.15_suppl.tps8586
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Brahmer, J. R., Lee, J.-S., Ciuleanu, T.-E., Bernabe Caro, R., Nishio, M., Urban, L., Audigier-Valette, C., Lupinacci, L., Sangha, R., Pluzanski, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01503 · Cited by 406
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008189 · Cited by 65
Tedesco, J., Jaradeh, M., & Vigneswaran, W. T. (2022) · Cancers · doi:10.3390/cancers14184415 · Cited by 12
Metadata
- Authors
- Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A. K., Fujimoto, N., Tsao, A. S., Mansfield, A. S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., & Zalcman, G.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 33
- Issue
- 5
- Pages
- 488-499
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4210792133
- Cited by
- 264
- References
- 44
- FWCI
- 32.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Ono Pharmaceutical
- Bristol-Myers Squibb
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.